IRVINE, CA / ACCESSWIRE / August 23, 2017 / Khang & Khang LLP (the 'Firm') announces a securities class action lawsuit against Ocular Therapeutix, Inc. ('Ocular' or the 'Company') (NASDAQ: OCUL). Investors who purchased or otherwise acquired Ocular shares from May 5, 2017 through July 6, 2017, inclusive (the 'Class Period'), are encouraged to contact the Firm before the September 5, 2017 lead plaintiff motion deadline.
If you purchased Ocular shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone at (949) 419-3834, or by e-mail at joon@khanglaw.com.
There has been no class certification in this case yet, and until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member as well.
According to the Complaint, during the Class Period, Ocular made false and/or misleading statements and/or failed to disclose: that the Company's management misled investors about DEXTENZA manufacturing issues, including that more than half of lots manufactured by Ocular contain bad product; that such manufacturing issues could endanger the approval of DEXTENZA by the FDA; and that as a result, the Company's public statements were materially false and misleading at all relevant times. When this news reached the public, Ocular's stock price lowered materially, which caused investors harm according to the Complaint.
If you want to learn more about this lawsuit, or if you have questions about this notice or your rights, please contact Joon M. Khang, Esq., a prominent litigator for almost two decades, by telephone at (949) 419-3834, or by e-mail at joon@khanglaw.com.
This press release may constitute Attorney Advertising in certain jurisdictions.
Contact
Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com
SOURCE: Khang & Khang LLP
